BiondVax FAQ

BiondVax was founded in 2003 by Dr. Ron Babecoff, based on the technology developed by former Copaxone developer, Professor Ruth Arnon of the Weizman Institute in Israel. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing this innovative flu vaccine.

BiondVax is an innovative biopharmaceutical company developing a Universal Flu Vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.

The company’s headquarters are in Israel, in the science and technology park adjacent to the Weismann Institute. The address: 14 Einstein Street, Ness Ziona, Israel. The company’s state-of-the-art GMP facility in Ness-Ziona houses its laboratories, production facilities and offices.

BiondVax has a team of 14 includes scientists, technicians, researchers, and administrative staff.

BiondVax legal counsel is Pearl Cohen Zedek Latzer Baratz, based in Israel and can be contacted on +972-3-607 3777.

BiondVax works with Ernst & Young in Israel and can be contacted on +972 3 623 2525.

BiondVax works with Gelbart-Kahana in Israel for its domestic investor relations program and GK, a subsidiary of Gelbart-Kahana for its international investor relations program. To contact investor relations please e-mail: or call +972 3 607 4717 in Israel or +1 646 201 9246 internationally.


Financial FAQ

The fiscal year ends on December 31 of each calendar year. First Quarter ends: March 31 Second Quarter ends: June 30 Third Quarter ends: September 30 Fourth Quarter ends: December 31.
Financial results are typically announced just prior to 3 months following the close of the quarter.
From May 2015, as BiondVax is a foreign filer for US SEC purposes. While it is not required to file a 10K or 10Q, Biondvax files its quarterly results and any important information under 6K filings with the SEC and files full year audited financial statements under a 20F filing. Prior to May 2015, Biondvax’s filings are all in Hebrew, filed with the Tel Aviv Stock Exchange.
The company historical financial statements are available in the investor relations section of the Company’s website.



Stock FAQ

In June 2007, BiondVax started trading on the Tel-Aviv Stock Exchange (TASE). In May 2015, the company listed American Depository Shares (ADS) on Nasdaq. One ADS represents 40 shares of BiondVax. In addition, the company has warrants outstanding which were issued together with its Nasdaq offering.
BiondVax’s shares are listed on the Tel Aviv Stock Exchange in Israel and under a Sponsored – Level III ADR program on Nasdaq in the United States. It also has warrants trading in the US. BiondVax will voluntarily delist from TASE in January, 2018.
BiondVax’s American Depository Shares (ADS) trade on Nasdaq under the ticker BVXV. BiondVax’s US warrants trade under the ticker BVXVW. BiondVax’s Tel-Aviv Stock Exchange (TASE) listed shares trade under the ticker BVXV. BiondVax will voluntarily delist from TASE in January, 2018.
As of October 30, 2017, BiondVax has approximately 261 million shares outstanding. There is a 40:1 ratio between shares and American Depository Shares. Thus  there are approximately 6.5 million American Depository Shares. In addition, the company has a further 1.76 million ADS warrants traded in the United States outstanding (convertible to70.5 million shares), convertible at $6.25.
BiondVax’s TASE listed shares traded under ISIN IL0011052045. BiondVax’s Nasdaq ADS trade under CUSIP 09073Q105 and warrants under CUSIP 09073Q113.
BNY Mellon manages the ADS program and can be contacted at